Process for manufacturing rosuvastatin potassium and crystalline and amorphous forms thereof

a technology of rosuvastatin and rosuvastatin, which is applied in the field of process for the manufacture of potassium salt of (e)74(4fluorophenyl)6isopropyl2methyl (methylsulfonyl) amino5pyrimidin5 -, can solve the problem of limited disclosure of 314 patents

Inactive Publication Date: 2010-10-28
CADILA HEALTHCARE LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However '314 patent is limited in its disclosure to an amorphous (powder) form of the calcium salt of Rosuvastatin, which is prepared by isolating its precursor sodium salt.
A powdery or amorphous form of a compound intended for pharmaceutical use may give rise to manufacturing problems and there is therefore a need to identify alternative salt of rosuvastatin that is crystalline salt.
Moreover various prior art teaches obtaining crystalline salts of Rosuvastatin but not the method to isolate the Rosuvastatin potassium salt or its purification.
The amorphous form has its advantages and disadvantages that it is not suitable from commercial point of view because, the amorphous product is difficult to isolate and the product is not obtained in high purity.
Moreover, it is difficult while handling amorphous product at various unit operation stages because of the problem of dusting, hence handling amorphous products requires installing special equipments to overcome health hazards.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

examples 1

Preparation of Amorphous Form of Rosuvastatin Potassium

[0047]In a 2 l four neck reaction flask equipped with a mechanical stirrer and temperature as well as pH monitoring facility, 625 ml of Methanol is added. To this reaction vessel 25.0 g Rosuvastatin protected diol of Formula—(IIa) is added under stirring. A solution thus obtained is cooled to 5-10° C., then the mixture of hydrochloric acid (7.5 ml) and water (52.5 ml) is added slowly within 20 minutes time. After complete addition, solution in the reaction flask is stirred it at 5-10° C. for 15 minutes. The resultant solution is warmed to 30-35° C. and stir for 45 minutes.

[0048]Reaction is monitored at this stage by Thin Layer Chromatography.

[0049]Again the stirred solution in the reaction vessel is cooled to 5-10° C. then slowly the solution of potassium hydroxide is added, which is made by dissolving 12.2 g of potassium in 122 ml of water at 5-10° C. The saponification is continued for 15 minutes under vigorous stirring at the...

example

Preparation of Crystalline Form of Rosuvastatin Potassium

[0052]In the mother liquor obtained from Example—1, 50 ml of acetonitrile is added and resultant solution is concentrated by distillation under vacuum and there after it is allowed to cool. Potassium salt of rosuvastatin obtained by filtration is crystalline form.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A process of manufacturing of Rosuvastatin Potassium of formula (I)is disclosed. The process comprises the steps of(a) treating Rosuvastatin protected compound of formula (II)wherein R1 and R2 are same or different having C1-C4 carbon atom or hydrogen or R1 and R2 can combine together to afford a cyclic structure comprising a junction atom as carbon or metal atom such as Si (silicon);with an inorganic base of the kind such as herein described having potassium as cation in a suitable solvent to form Rosuvastatin potassium;(b) isolating Rosuvastatin potassium.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a process for the manufacture of potassium salt of (E) -7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl)amino]5-pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acidBACKGROUND OF THE INVENTION[0002]US RE 37314 (Reissue of U.S. Pat. No. 5,260,440) discloses Rosuvastatin that is chemically known as (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid and its salts, which are HMG CoA reductase inhibitors and useful in the treatment of hypercholesterolemia, hyperlipoproteinemia and atherosclerosis.[0003]The '314 patent discloses the existence of Rosuvastatin in the generic formula and its various alkali metal salts i.e., lithium, sodium, potassium, and cesium, as well as alkaline earth metal salts are beryllium, magnesium, and calcium. However '314 patent is limited in its disclosure to an amorphous (powder) form of the calcium salt of Rosuvasta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D239/42
CPCC07D239/42A61P3/06
Inventor PATEL, DHIMANT JASUBHAIKUMAR, RAJIVAGARWAL, VIRENDRA KUMAR
Owner CADILA HEALTHCARE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products